Northwestern Mutual Wealth Management’s Adial Pharmaceuticals ADIL Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7	Buy	+4	New	+$14	﹤0.01%	4090

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Northwestern Mutual Wealth Management's ADIL Position: Q1 2026 in Review

Northwestern Mutual Wealth Management opened a new position in Adial Pharmaceuticals (ADIL) in Q1 2026: 4 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #4090 among its holdings.

14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

Northwestern Mutual Wealth Management held 4 shares of Adial Pharmaceuticals worth $7 as of Q1 2026.
Adial Pharmaceuticals was a new Northwestern Mutual Wealth Management position in Q1 2026.
Adial Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #4090 holding.
14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.